Cite
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
MLA
Oza, Amit M., et al. “Standard Chemotherapy with or without Bevacizumab for Women with Newly Diagnosed Ovarian Cancer (ICON7): Overall Survival Results of a Phase 3 Randomised Trial.” The Lancet. Oncology, vol. 16, no. 8, Aug. 2015, pp. 928–36. EBSCOhost, https://doi.org/10.1016/S1470-2045(15)00086-8.
APA
Oza, A. M., Cook, A. D., Pfisterer, J., Embleton, A., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., Park-Simon, T.-W., Rustin, G., Joly, F., Mirza, M. R., Plante, M., Quinn, M., Poveda, A., Jayson, G. C., Stark, D., … Perren, T. J. (2015). Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. The Lancet. Oncology, 16(8), 928–936. https://doi.org/10.1016/S1470-2045(15)00086-8
Chicago
Oza, Amit M, Adrian D Cook, Jacobus Pfisterer, Andrew Embleton, Jonathan A Ledermann, Eric Pujade-Lauraine, Gunnar Kristensen, et al. 2015. “Standard Chemotherapy with or without Bevacizumab for Women with Newly Diagnosed Ovarian Cancer (ICON7): Overall Survival Results of a Phase 3 Randomised Trial.” The Lancet. Oncology 16 (8): 928–36. doi:10.1016/S1470-2045(15)00086-8.